



GLOBAL VIRUS NETWORK & MONACO COVID-19 DIAGNOSTIC CONFERENCE: PROMISES AND CHALLENGES

UNDER THE HIGH PATRONAGE OF HSH PRINCE ALBERT II OF MONACO

Thursday, December 02, 2021 - Friday, December 03, 2021

ORGANIZERS

GLOBAL VIRUS NETWORK



The [Global Virus Network](#) is a coalition of renowned virologists representing 65 Centers of Excellence and 11 affiliates in 35 countries; scientists from academia and industry are collectively working to advance knowledge about viral pathogenesis and developing diagnostics, vaccines, and antiviral drugs and therapy to protect the public health. The mission of GVN include research, education and advocacy, the merging of these highly renowned scientists offering an invaluable resource for expertise. Moreover, effort of the GVN extend to rapid and efficient responses to the current COVID19 pandemic and to prepare for future pandemics.



ROBERT GALLO, MD

Co-Founder and International Scientific Advisor of the GVN; the Homer and Martha Gudelsky Distinguished Professor in Medicine; Co-Founder & Director, Institute of Human Virology at the University of Maryland School of Medicine, USA

CHRISTIAN BRÉCHOT, MD, PHD

President of GVN; Professor, Sr. Associate Dean for Research for Global Affairs; Associate Vice President, International Partnerships & Innovation, Morsani College of Medicine USF Health University of South Florida, USA



MONACO SCIENTIFIC CENTER



Dedicated to scientific research, fundamental and applied, the work developed by the teams of the [Monaco Scientific Center](#) (CSM) are grouped into three departments: Marine Biology, Polar Biology And Medical Biology. The primary concern of researchers in these departments is to study the bases of the functioning of organisms in order to better understand, and therefore better anticipate, the effects of environmental stresses (Physiology of Conservation) or therapeutic treatments (Translational Biology).



PATRICK RAMPAL, MD

President of the Scientific Center of Monaco; Head of the Scientific Steering Committee, Monaco

FOUNDATION PRINCE ALBERT II



In June 2006, H.S.H. Prince Albert II of Monaco decided to create His Foundation in order to respond to the worrying threats facing our planet. The Prince Albert II of Monaco Foundation (P.A.I.2) works to protect the environment and promote sustainable development and supports initiatives by public and private organizations in the fields of research, technological innovation and socially conscious practices. The Foundation supports projects in three priority geographical areas: the Mediterranean basin, the polar regions and the least developed countries. For more information, visit www.fpa2.org



OLIVER WENDEN

Vice-President & CEO of the Prince Albert II Monaco foundation, Monaco

FOUNDATION MÉRIEUX



The mission of the [Fondation Mérieux](#) is to contribute to global health by strengthening local capacities in developing countries to reduce the impact of infectious diseases on vulnerable populations. The foundation works in over 20 countries worldwide, in regions prone to infectious outbreaks by working closely with local and international partners. The foundation engages the public and private sectors and embrace a One Health approach, crossing boundaries between human and veterinary medicine.



ALAIN MÉRIEUX

President of the Mérieux Foundation; Chairman of Institut Mérieux, France

MARC BONNEVILLE, DVM, PHD

Vice president of Medical and Scientific Affairs at Institut Mérieux; Scientific and Medical director; Deputy General Manager Fondation Mérieux, France



[Click here to register](#)

Continue for the workshop agenda



WORKSHOP AGENDA

IN PERSON IN MONACO & ONLINE THROUGH ZOOM

• THURSDAY, DECEMBER 02, 2021 •

• 2:00-6:05 PM, CET •

• Opening Remarks

2:00-2:20



Drs. Robert Gallo and Christian Bréchet, GVN

Dr. Patrick Rampal, CSM

Mr. Alain Mérieux, Fondation Mérieux

• Keynote Presentations

2:20-2:40



Dr. Damian Purcell, Doherty Institute, GVN

— Teaming diagnostics, genomics and innovation to control the pandemic in Australia.

2:40-3:00



Dr. Christopher Brooke, University of Illinois

— Daily longitudinal sampling of early SARS-CoV-2 infection reveals variation in test sensitivity and viral tissue distribution

• Immunology Testing

3:00-3:15



Dr. Oliver Wenden, Chair, Prince Albert II Foundation

Dr. Linfa Wang, DUKE-NUS Medical School, GVN

— Surrogate virus neutralization test (sVNT) for combating SARS2 and getting ready for SARS3

3:15-3:30



Dr. Thomas Althaus, CSM

— SARS-CoV-2 serology: a national programme in Monaco

3:30-3:45



Dr. Isabella Eckerle, University of Geneva

— SARS-CoV-2 Antibody Testing - Tools for Monitoring Epidemiology, Disease & Vaccination

Q&A

3:45-3:55

Break

3:55-4:05

• Saliva Testing Pros & Cons

4:05-4:20



Dr. Andrey V. Vasin, Chair, Research Institute of Influenza, GVN

Dr. Joseph R. Fauver, Yale School of Public Health

— Saliva is a robust sample type for SARS-CoV-2 diagnostics and whole genome sequencing.

4:20-4:35



Dr. Robert Garry, Tulane University School of Medicine, GVN

— Rapid tests for emerging pathogens

Q&A

4:35-4:45

• Rapid Testing

4:45-5:00



Dr. YoungMee Jee, Chair, Institut Pasteur Korea, GVN

Dr. Pardis Sabeti, Harvard T.H. Chan School, GVN

— Sentinel: Preempting and Responding to Pandemics in the Genomic and Information Age

5:00-5:15



Dr. Cesar de la Fuente-Nunez, University of Pennsylvania

— Machine Biology for Infectious Diseases

Q&A

5:15-5:25

• Biomarkers for Clinical Diagnostics

5:25-5:40



Florence Komurian-Pradel, Co-Chair, Fondation Mérieux

Dr. Sophie Trouillet-Assant, Rhône

— Type I interferon response in COVID-19 patients

5:40-5:55



Dr. John Tsang, NIAID, NIH

— Multimodal and single cell predictive markers of COVID-19 disease severity

Q&A

5:55-6:05

WORKSHOP AGENDA

IN PERSON IN MONACO & ONLINE THROUGH ZOOM

• **FRIDAY, DECEMBER 03, 2021** •

• 2:00-6:00 PM, CET •

• Opening Remarks

2:00-2:20



Dr. Marc Bonneville, *Foundation Mérieux*

Dr. Bill Rodriguez, *FIND*

• Keynote Presentations

2:20-2:40



Dr. William Hall, *University College Dublin, GVN*

— Molecular Characterization and Rapid Detection of Covid-19 Variants in Ireland

2:40-3:00



Dr. Donald Ingber, *The Wyss Institute at Harvard, GVN*

— Multiplexed point-of-care COVID19 diagnostics

3:00-3:20



Dr. Sergio Carmona, *FIND*

3:20-3:40



Dr. Philippe Duneton, *Unitaid*

• Genomic Sequencing Analysis & Diagnostics of Variants of Concern

3:40-3:55



Dr. Christine V. F. Carrington, *Chair, UWI, St. Augustine, GVN*

Dr. Richard Scheuermann, *J. Craig Venter Institute, GVN*

— Early Detection of SARS-CoV-2 Variants of Concern From Genomic Sequence Analysis

3:55-4:10



Dr. Eric Voiglio, *Directorate of Health Affairs, Monaco*

— Comirnaty effectiveness on Delta variant transmission in Monaco

Q&A

4:10-4:20

Break

4:20-4:35

• Implementation of Diagnostic Tests in a Global Health Strategy

4:35-5:40



Ms. Zoë Mullan, *Moderator, The Lancet Global Health*

Dr. Juliette Tuakli, *United Way*

Dr. Renaud Jonquière, *BioMérieux*

Dr. Gavin Cloherty, *Abbott, GVN*

Dr. Maxime Maignan, *Roche Diagnostics*

Dr. Michel Kazatchkine, *Global Health Centre of the Graduate Institute for International and Development Studies in Geneva*

• Workshop Summary

5:40-5:50



Dr. Christian Bréchet, *GVN*

• Closing Remarks

5:50-6:00



H.S.H Prince Albert II, *Monaco*

For any further inquiries contact:



GVN:
Linman Li,
linmanli@gvn.org



Fondation Mérieux:
Marc Bonneville,
marc.bonneville@fondation-merieux.com



Monaco Scientific Center:
Thomas Althaus,
talthaus@gouv.mc